Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa
July 18, 2017 08:05 ET
|
Abeona Therapeutics Inc
Pivotal Phase 3 clinical trial is planned to commence in early 2018 EB-101 gene therapy for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) has demonstrated promising efficacy and...
Abeona Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
June 02, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, June 02, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
May 25, 2017 08:05 ET
|
Abeona Therapeutics Inc
Abeona’s Third Gene Therapy Program to Receive FDA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in...
Abeona Therapeutics to Present at Multiple Upcoming Conferences
May 19, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 19, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference
May 02, 2017 08:05 ET
|
Abeona Therapeutics Inc
--EB-101 Demonstrates Significant Wound Healing (defined as greater than 50% healed) in 100% of Treated Wounds (36/36) at 3 Months; 89% (32/36) at 6 months, 83% (20/24) at 12 months, 88% (21/24) at 24...
Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting
April 25, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, April 25, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies...
Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights
March 31, 2017 08:05 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 31, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing...
Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences
March 13, 2017 08:15 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 13, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
March 08, 2017 08:15 ET
|
Abeona Therapeutics Inc
Abeona’s Fourth Gene Therapy Program to Receive EMA Orphan Designation EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) has Demonstrated Promising Efficacy and Safety in...
Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference
March 07, 2017 07:45 ET
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, March 07, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) a leading clinical-stage biopharmaceutical company focused on developing therapies for...